Cancer Institute A national cancer institute
designated cancer center

Beth Martin-Kool

Publication Details

  • High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies MUSCLE & NERVE Lin, P. T., Martin, B. A., Weinacker, A. B., So, Y. T. 2006; 33 (3): 433-435

    Abstract:

    We describe a 48-year-old woman with seronegative myasthenia gravis (MG) and high-titer of anti-MuSK antibody. She had severe bulbar and respiratory weakness with minimal limb weakness for 2 years. Her disease responded poorly to all the conventional immunosuppressive regimens. Treatment with immunoablative dose of cyclophosphamide led to dramatic and sustained remission of her symptoms. High-dose cyclophosphamide is an effective alternative in patients with unusually refractory disease.

    View details for DOI 10.1002/mus.20411

    View details for Web of Science ID 000235646300016

    View details for PubMedID 16116645

Stanford Medicine Resources:

Footer Links: